The CEA/PCI ratio has been suggested by Kozman et al. in 2017 [4] as a novel approach to calculate both tumour burden (PCI) and activity (pre-operative carcinoembryonic antigen) in a unified score, with potential prognostic impact for both overall survival (OS) and recurrence free survival (RFS). The gene discussed is CEACAM5; the disease is neoplasm.